SynthesisArthritis research & therapy2022
The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis.
Synthesis in Arthritis research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 75 citations in OpenAlex.
- Dense Plasma Cell Infiltrates Foster Stromal Desmoplasia and Immune Evasion in Oral Squamous Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- Review
- Article
- SARS-CoV2 and Anti-COVID-19 mRNA Vaccines: Is There a Plausible Mechanistic Link with Cancer?Cancers · 2025Review
- Coexistence of IgG4-Related Disease and Renal Anastomosing Hemangioma: A Rare Diagnostic Challenge.Internal medicine (Tokyo, Japan) · 2025Article
- Increased cancer risk in patients with IgG4-related disease in a nationwide South Korean cohort, 2012-2021.Scientific reports · 2025Article
- Adherence to United European Gastroenterology Guidelines on Diagnosis and Therapy of Immunoglobulin-G4-Related Digestive Disease.United European gastroenterology journal · 2025Article
- Cancer Risk in Autoimmune and Immune-Mediated Diseases: A Narrative Review for Practising Clinicians.Journal of clinical medicine · 2025Review
- IgG4-related lung disease with pulmonary lesions and recurrent pleural effusion: A case of report.Radiology case reports · 2025Article
- Diffuse large B-cell lymphoma with rapid kidney enlargement after induction of hemodialysis in a patient with IgG4-related disease.CEN case reports · 2025Article
- Clinical characterization of malignant lymphoma mimicking IgG4-related disease.Clinical rheumatology · 2025Article
- Article
- IgG4-related Disease Concomitant with Diffuse Large B-cell Lymphoma.Internal medicine (Tokyo, Japan) · 2025Article
- The relationship between immunoglobulin G4-related disease and malignancy.Reumatologia · 2025Article
- Pharmacological Management of IgG4-Related Disease: From Traditional to Mechanism-Based Targeted Therapies.Drugs & aging · 2025Review
- Epigenetic age acceleration and methylation differences in IgG4-related cholangitis and primary sclerosing cholangitis.Clinical epigenetics · 2025Article
- The regulatory role of immune microenvironment-related cells and pathways in the pathogenesis of keloids.Frontiers in immunology · 2025Review
- IgG4-related disease-like lesion arising within a well-differentiated liposarcoma/an atypical lipomatous tumor: two cases report.Frontiers in oncology · 2025Article
- IgG4-related disease - focus on digestive system involvement.Frontiers in immunology · 2025Review
- Factors related to elevated serum immunoglobulin G4 (IgG4) levels in a Japanese general population.Arthritis research & therapy · 2024Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe relationship between IgG4-related disease (IgG4-RD) and the risk of malignancy is still controversial. This article focused on assessing the risk of cancer in patients with IgG4-RD by meta-analysis.
methodsWe conducted a systematic review of the literature and meta-analysis characterizing the associated risk of overall malignancy and four site-specific malignancies (pancreas, lung, gastric and lymphoma) in patients with IgG4-RD. A search from 2003 to 2020 was performed using specified terms from PubMed, Embase, Web of Science and SinoMed. Random-effects model analysis was used to pool standardized incidence ratios (SIRs) and 95% confidence intervals (CIs). Subgroup and sensitivity analyses were conducted to clarify the heterogeneity of the included studies. Begg's funnel plot and Egger's linear regression test were used to evaluate the bias of the meta-analysis. A P value < 0.05 indicated the existence of publication bias.
resultsA total of 10 studies were included in the article. The overall SIR estimates suggested an increased risk of overall cancer in IgG4-RD patients (SIR 2.57 95% CI 1.72-3.84) compared with the general population. The specific SIRs for pancreas and lymphoma were higher than those of the general population in IgG4-RD patients (SIR 4.07 95% CI 1.04-15.92, SIR 69.17 95% CI 3.91-1223.04, respectively). No significant associations were revealed in respiratory and gastric cancer (SIR 2.14 95% CI 0.97-4.75, SIR 0.95 95% CI 0.24-3.95, respectively). Four studies were found to be the major sources of heterogeneity by sensitivity analysis. There was no evidence of publication bias via Egger's test.
conclusionCompared with the general population, patients with IgG4-RD appear to have a higher risk of overall cancer, especially pancreatic and lymphoma. The risk of lung and gastric cancer was not different between IgG4-RD patients and the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.